| Characteristic |
Standard Care Group
n=120 (%) |
Intervention Care Group
n=120 (%) |
| Sex |
|
|
| Male |
99(82.5) |
89 (74.2) |
| Female |
21 (17.5) |
31 (25.8) |
| CD4+ T-cell count (cells/µl) |
|
|
| ≤ 350 |
114 (95) |
113 (94.1) |
| 350-500 |
4 (3.3) |
4 (3.3) |
| >500 |
2 (1.7) |
3 (2.6) |
| Age (years) |
|
|
| 21-40 |
51 (42.5) |
63 (52.6) |
| 41-60 |
67 (55.8) |
52 (43.3) |
| > 60 |
2 (1.7) |
5 (4.1) |
| ART regimen |
|
|
| Tenofovir + Emtricitabine+ Efavirenz |
52 (43.3) |
52 (43.3) |
| Zidovudine + Lamivudine+Nevirapine |
53 (44.1) |
45 (37.5) |
| Stavudine + Lamivudine+Nevirapine |
15 (12.6) |
23 (19.2) |
| Education status |
|
|
| Literate |
71 (59.1) |
58 (48.3) |
| Illeterate |
49 (40.9) |
62 (51.7) |
| Employment status |
|
|
| Employed |
94 (78.3) |
88 (73.3) |
| Unemployed |
26 (21.7) |
32 (26.7) |
| Duration of use of antiretroviral therapy |
|
|
| Less than two years |
113(94.1) |
109(90.9) |
| Greater than two years |
7(5.9) |
11(9.1) |
